When Cancer is Just the Beginning

When Cancer is Just the Beginning Mary Slattery at her home in New Jersey. Dustin Fenstermacher / wonderful machine Rarely, the body reacts to cancer by generating immune cells that chew their way into the brain. Could research with this handful of patients create a new therapeutic cancer vaccine? By Julia C. Mead • Photography by Dustin Fenstermacher Article Extras 1 But the antibody in Slattery's spinal fluid signified something more sinister: An immune re

Written byJulia C. Mead
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

By Julia C. Mead • Photography by Dustin Fenstermacher

1 But the antibody in Slattery's spinal fluid signified something more sinister: An immune response to her cancer, theoretically arrested more than a year earlier, was so ferocious that it had chewed through the blood-brain barrier and into her cerebellum. Specifically, it had gnawed on Purkinje neurons that, like ovarian tumor cells, also express cdr2. Slattery had paraneoplastic cerebellar degeneration.

PCD is one of about a dozen paraneoplastic neurologic disorders (PNDs).2 Some, including PCD, are defined by an immune response to a malignancy that remains at a distance from the brain. PCD, associated with ovarian, breast, and small-cell lung cancer, is rare; accepted estimates put it at 1 in 10,000 cancer patients.

Significant improvement in its neurological condition is also rare. More often than not, the level of disability hits a plateau within just a few weeks. The menu of symptoms ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies